Wall Street analysts expect BeiGene, Ltd. (NASDAQ:BGNE) to announce earnings per share (EPS) of $0.86 for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for BeiGene’s earnings, with estimates ranging from ($1.10) to $4.72. BeiGene posted earnings of ($1.05) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 181.9%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 28th.
According to Zacks, analysts expect that BeiGene will report full year earnings of ($3.30) per share for the current year, with EPS estimates ranging from ($5.59) to $0.87. For the next fiscal year, analysts expect that the company will post earnings of ($5.06) per share, with EPS estimates ranging from ($5.96) to ($4.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for BeiGene.
BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the business earned ($1.08) EPS.
BeiGene (NASDAQ:BGNE) opened at $80.43 on Thursday. BeiGene has a twelve month low of $26.43 and a twelve month high of $118.95. The company has a quick ratio of 8.38, a current ratio of 8.38 and a debt-to-equity ratio of 0.57.
In related news, CEO John Oyler sold 25,054 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $83.06, for a total value of $2,080,985.24. Following the sale, the chief executive officer now owns 491,891 shares of the company’s stock, valued at $40,856,466.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Amy C. Peterson sold 3,601 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the sale, the chief marketing officer now directly owns 1,201 shares in the company, valued at approximately $99,634.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 179,612 shares of company stock worth $14,531,763. Insiders own 19.90% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in BeiGene in the second quarter valued at about $111,000. Quantbot Technologies LP bought a new stake in BeiGene in the third quarter valued at about $160,000. Renaissance Technologies LLC bought a new stake in BeiGene in the first quarter valued at about $238,000. Profund Advisors LLC bought a new stake in BeiGene in the second quarter valued at about $248,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in BeiGene in the third quarter valued at about $248,000. 52.09% of the stock is currently owned by institutional investors and hedge funds.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.